On the public citation graph

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )

0 signed · 90 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/hep.20466openalex-snapshot
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
inferredcites →https://doi.org/10.1002/hep.21496openalex-snapshot
The NAFLD fibrosis score
inferredcites →https://doi.org/10.1002/hep.28287openalex-snapshot
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.29367openalex-snapshot
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
inferredcites →https://doi.org/10.1002/hep.30429openalex-snapshot
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1002/hep.30626openalex-snapshot
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
inferredcites →https://doi.org/10.1007/s00125-003-1263-9openalex-snapshot
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
inferredcites →https://doi.org/10.1016/j.cgh.2014.12.014openalex-snapshot
Accuracy of Fibroscan, Compared With Histology, in Analysis of Liver Fibrosis in Patients With Hepatitis B or C: A United States Multicenter Study
inferredcites →https://doi.org/10.1016/j.jhep.2018.09.024openalex-snapshot
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
inferredcites →https://doi.org/10.1016/j.jhep.2019.09.018openalex-snapshot
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
inferredcites →https://doi.org/10.1016/j.molmet.2020.101154openalex-snapshot
Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/s0140-6736(15)00803-xopenalex-snapshot
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
inferredcites →https://doi.org/10.1016/s2213-8587(14)70032-4openalex-snapshot
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
inferredcites →https://doi.org/10.1016/s2213-8587(18)30154-2openalex-snapshot
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
inferredcites →https://doi.org/10.1038/nrgastro.2017.109openalex-snapshot
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
inferredcites →https://doi.org/10.1042/cs20170987openalex-snapshot
Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
inferredcites →https://doi.org/10.1053/gast.2001.25540openalex-snapshot
Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese
inferredcites →https://doi.org/10.1053/j.gastro.2007.04.068openalex-snapshot
Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects
inferredcites →https://doi.org/10.1053/j.gastro.2008.06.047openalex-snapshot
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.005openalex-snapshot
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa060326openalex-snapshot
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa0907929openalex-snapshot
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa2028395openalex-snapshot
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1111/dom.12417openalex-snapshot
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial
inferredcites →https://doi.org/10.1111/dom.13285openalex-snapshot
Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus
inferredcites →https://doi.org/10.1111/febs.13992openalex-snapshot
Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes
inferredcites →https://doi.org/10.1111/hepr.12351openalex-snapshot
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients ( LEAN ‐ J )
inferredcites →https://doi.org/10.1111/j.1572-0241.2005.00341.xopenalex-snapshot
The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999-2002
inferredcites →https://doi.org/10.1136/bmjdrc-2019-000904openalex-snapshot
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications
inferredcites →https://doi.org/10.1136/gut.2007.146019openalex-snapshot
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
inferredcites →https://doi.org/10.1148/radiol.12112344openalex-snapshot
Liver Metabolite Concentrations Measured with1H MR Spectroscopy
inferredcites →https://doi.org/10.1148/radiol.12120896openalex-snapshot
Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis
inferredcites →https://doi.org/10.1177/1479164118825376openalex-snapshot
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
inferredcites →https://doi.org/10.1186/2050-7771-1-7openalex-snapshot
Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
inferredcites →https://doi.org/10.1210/jc.2004-1133openalex-snapshot
β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
inferredcites →https://doi.org/10.1210/jc.87.6.2784openalex-snapshot
Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients
inferredcites →https://doi.org/10.2337/dc05-2445openalex-snapshot
The Effect of Pioglitazone on the Liver
inferredcites →https://doi.org/10.2337/dc10-2229openalex-snapshot
Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
inferredcites →https://doi.org/10.2337/dc19-0167openalex-snapshot
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
inferredcites →https://doi.org/10.2337/dc19-1071openalex-snapshot
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc19-1113openalex-snapshot
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
inferredcites →https://doi.org/10.2337/dc20-0978openalex-snapshot
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
inferredcites →https://doi.org/10.2337/diacare.22.9.1462openalex-snapshot
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.
inferredcites →https://doi.org/10.3389/fmed.2021.795421openalex-snapshot
Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population
inferredcites →https://doi.org/10.3390/diagnostics11010098openalex-snapshot
Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
inferredcites →https://doi.org/10.7326/m15-1774openalex-snapshot
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/mrm.29860openalex-snapshot
Comparative review of algorithms and methods for chemical‐shift‐encoded quantitative fat‐water imaging
inferred← citeshttps://doi.org/10.1007/s00125-026-06855-7openalex-snapshot
Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferred← citeshttps://doi.org/10.1007/s00592-023-02115-xopenalex-snapshot
AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s10238-026-02112-8openalex-snapshot
Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions
inferred← citeshttps://doi.org/10.1007/s12020-024-03715-5openalex-snapshot
Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
inferred← citeshttps://doi.org/10.1007/s42000-023-00493-zopenalex-snapshot
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.cld.2025.04.003openalex-snapshot
The Liver in Diabetes and Metabolic Syndrome
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.jhepr.2026.101798openalex-snapshot
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
inferred← citeshttps://doi.org/10.1016/j.metop.2025.100424openalex-snapshot
Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.phymed.2025.157180openalex-snapshot
Obacunone ameliorates high-fat diet-induced MAFLD by regulating the PPARγ-FABP1/CD36 axis and the gut-liver crosstalk
inferred← citeshttps://doi.org/10.1016/j.zemedi.2022.12.004openalex-snapshot
Automated shape-independent assessment of the spatial distribution of proton density fat fraction in vertebral bone marrow
inferred← citeshttps://doi.org/10.1097/ms9.0000000000001875openalex-snapshot
The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
inferred← citeshttps://doi.org/10.1111/dom.14950openalex-snapshot
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction
inferred← citeshttps://doi.org/10.1111/dom.15222openalex-snapshot
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome
inferred← citeshttps://doi.org/10.1111/dom.15358openalex-snapshot
One‐hour post‐load glucose levels are associated with hepatic steatosis assessed by transient elastography
inferred← citeshttps://doi.org/10.1111/dom.16049openalex-snapshot
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
inferred← citeshttps://doi.org/10.1136/bmjdrc-2024-004199openalex-snapshot
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects
inferred← citeshttps://doi.org/10.1136/flgastro-2024-102856openalex-snapshot
Role of anti-diabetic medications in the management of MASLD
inferred← citeshttps://doi.org/10.1186/s12916-024-03518-5openalex-snapshot
Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines
inferred← citeshttps://doi.org/10.1186/s13020-024-00894-1openalex-snapshot
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
inferred← citeshttps://doi.org/10.1210/clinem/dgae872openalex-snapshot
Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study
inferred← citeshttps://doi.org/10.1515/bmc-2025-0059openalex-snapshot
Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2134695/v1openalex-snapshot
AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2134695/v2openalex-snapshot
AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3982234/v1openalex-snapshot
The determination of the comparative effect of Ertugliflozin, Pioglitazone, and Metformin on patients of non-alcoholic fatty liver disease in type 2 diabetes mellitus.
inferred← citeshttps://doi.org/10.2174/0118715230325278240821053346openalex-snapshot
Molecular Docking, Pharmacophore Modeling and ADMET Prediction of Novel Heterocyclic Leads as Glucokinase Activators
inferred← citeshttps://doi.org/10.21873/invivo.13178openalex-snapshot
Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.2337/9781580408462-ch01openalex-snapshot
Pharmacologic Therapy for Type 1 Diabetes
inferred← citeshttps://doi.org/10.2337/9781580408462-ch04openalex-snapshot
Pharmacologic Therapy for Type 2 Diabetes
inferred← citeshttps://doi.org/10.2337/dc23-1646openalex-snapshot
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
inferred← citeshttps://doi.org/10.2337/dc25-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
inferred← citeshttps://doi.org/10.2337/dc25-s009openalex-snapshot
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
inferred← citeshttps://doi.org/10.2337/dc26-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
inferred← citeshttps://doi.org/10.2337/dc26-s009openalex-snapshot
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
inferred← citeshttps://doi.org/10.2337/dci24-0094openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
inferred← citeshttps://doi.org/10.3389/fendo.2024.1394805openalex-snapshot
Gluco-regulation & type 2 diabetes: entrenched misconceptions updated to new governing principles for gold standard management
inferred← citeshttps://doi.org/10.3389/fphar.2025.1577201openalex-snapshot
Albiflorin inhibits inflammation to improve liver fibrosis by targeting the CXCL12/CXCR4 axis in mice
inferred← citeshttps://doi.org/10.3389/fphar.2025.1582258openalex-snapshot
Research and application of medicines for treating liver fibrosis: current status and prospects
inferred← citeshttps://doi.org/10.4252/wjsc.v17.i11.111162openalex-snapshot
Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.5114/amsad/151046openalex-snapshot
Pioglitazone in diabetic kidney disease: forgotten but not gone
inferred← citeshttps://doi.org/10.5114/amsad/202298openalex-snapshot
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
inferred← citeshttps://doi.org/10.5812/amh-144009openalex-snapshot
The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.